Our top pick for
Ambev S.A is a beverages-brewers business based in the US. Ambev S-A shares (ABEV) are listed on the NYSE and all prices are listed in US Dollars. Ambev S-A employs 50,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.62|
|52-week range||$2.07 - $3.95|
|50-day moving average||$2.86|
|200-day moving average||$3.16|
|Wall St. target price||$3.37|
|Dividend yield||$0.49 (18.63%)|
|Earnings per share (TTM)||$0.16|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-6.09%|
|1 month (2021-09-24)||-10.27%|
|3 months (2021-07-23)||-17.87%|
|6 months (2021-04-23)||-10.27%|
|1 year (2020-10-23)||4.38%|
|2 years (2019-10-24)||-44.61%|
|3 years (2018-10-24)||4.21|
|5 years (2016-10-24)||6.26|
Valuing Ambev S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ambev S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ambev S-A's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Ambev S-A shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ambev S-A's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2156. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ambev S-A's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ambev S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.8 billion.
The EBITDA is a measure of a Ambev S-A's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$66.5 billion|
|Operating margin TTM||25.12%|
|Gross profit TTM||$31.3 billion|
|Return on assets TTM||8.5%|
|Return on equity TTM||19.16%|
|Market capitalisation||$41.7 billion|
TTM: trailing 12 months
There are currently 40.6 million Ambev S-A shares held short by investors – that's known as Ambev S-A's "short interest". This figure is 25.3% down from 54.4 million last month.
There are a few different ways that this level of interest in shorting Ambev S-A shares can be evaluated.
Ambev S-A's "short interest ratio" (SIR) is the quantity of Ambev S-A shares currently shorted divided by the average quantity of Ambev S-A shares traded daily (recently around 29.0 million). Ambev S-A's SIR currently stands at 1.4. In other words for every 100,000 Ambev S-A shares traded daily on the market, roughly 1400 shares are currently held short.
However Ambev S-A's short interest can also be evaluated against the total number of Ambev S-A shares, or, against the total number of tradable Ambev S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ambev S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Ambev S-A shares in existence, roughly 0 shares are currently held short) or 0.0092% of the tradable shares (for every 100,000 tradable Ambev S-A shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ambev S-A.
Find out more about how you can short Ambev S-A stock.
Dividend payout ratio: 53.14% of net profits
Recently Ambev S-A has paid out, on average, around 53.14% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.54% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Ambev S-A shareholders could enjoy a 0.54% return on their shares, in the form of dividend payments. In Ambev S-A's case, that would currently equate to about $0.49 per share.
Ambev S-A's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Ambev S-A's most recent dividend payout was on 3 February 2021. The latest dividend was paid out to all shareholders who bought their shares by 13 January 2021 (the "ex-dividend date").
Ambev S-A's shares were split on a 5:1 basis on 10 November 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Ambev S-A shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Ambev S-A shares which in turn could have impacted Ambev S-A's share price.
Over the last 12 months, Ambev S-A's shares have ranged in value from as little as $2.0677 up to $3.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Ambev S-A's is 0.9515. This would suggest that Ambev S-A's shares are less volatile than average (for this exchange).
Ambev S. A. , through its subsidiaries, produces, distributes, and sells beer, draft beer, carbonated soft drinks (CSD), other non-alcoholic beverages, malt, and food products in the Americas. It operates through three segments: Brazil; Central America and the Caribbean; Latin America South; and Canada. The company offers beer primarily under the Skol, Brahma, Antarctica, Brahva, Brahva Gold, Extra, Budweiser, Bud Light, Stella Artois, Corona, Modelo Especial, Beck, Leffe, Hoegaarden, Bucanero, Cristal, Mayabe, Cacique, Presidente, Brahma Light, President Light, Bohemia, The One, Banks, Deputy, Quilmes Clásica, Paceña, Taquiña, Huari, Becker, Cusqueña, Pilsen, Ouro Fino, Patricia, Michelob Ultra, Busch, Labatt Blue, Alexander Keith's, and Kokanee brands. It also provides bottled water, isotonic beverages, energy drinks, coconut water, powdered and natural juices, and ready-to-drink teas under the Guaraná Antarctica, Natu, Gatorade, H2OH!, Lipton Iced Tea, Fusion, Do Bem, Pepsi, Canada Dry, Squirt, Red Rock, Pepsi-Cola, Seven Up, Nutrl, and Palm Bay and Mike's brands, as well as For Me wellness shots, a functional beverage. Ambev S.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.